Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55).
IC50&Target
Human Endogenous Metabolite
CB1
CB2
Microbial Metabolite
GPR18/GPR55
体外研究
Anandamide, acting via CB2 receptors, alleviates lipopolysaccharide (LPS)-induced neuroinflammation in rat primary microglial cultures. The endocannabinoid system modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2), although endocannabinoids, especially Anandamide (AEA), can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55.
体内研究
Anandamide is an endocannabinoid binding both CB1R and CB2R. To evaluate the impact of CBR activation on whole-body glucose homeostasis, glucose tolerance is assessed after a single intraperitoneal Anandamide injection (10 mg/kg). The increase in glycemia in response to glucose ingestion is considerably smaller in mice treated with Anandamide compared with control, and this is associated with an improvement of glucose tolerance as illustrated by the AUC0-2h calculations.
分子式
C22H37NO2
分子量
347.53
CAS号
94421-68-8
中文名称
花生四烯酸乙醇胺
运输条件
Room temperature in continental US; may vary elsewhere.